GlaxoSmithKline overhauls sales practices after scandals [1]

A no entry sign is pictured outside the GlaxoSmithKline building in Hounslow, west London June 18, 2013.
Credit: Reuters/Luke MacGregor
 

The initiative represents a bid by Britain's biggest drugmaker to get ahead of its critics by addressing potential conflicts of interest that could put commercial interests ahead of the best outcome for patients.

It comes amid a major bribery investigation in China [2], where police have accused GlaxoSmithKline (GSK) of funneling up to 3 billion yuan [3] ($494 million) to travel agencies to facilitate bribes to boost its drug sales.

More: Reuters.com [4]